Stoke Therapeutics Insider Allan Jonathan Files Form 4

TL;DR

**Insider Allan Jonathan just filed a Form 4 for Stoke Therapeutics, signaling a change in ownership.**

AI Summary

This Form 4 filing indicates that Allan Jonathan, a reporting person for Stoke Therapeutics, Inc., filed a statement of changes in beneficial ownership of securities on March 24, 2026, for a period ending March 20, 2026. While the filing itself doesn't detail specific transactions, it signals that an insider's holdings in Stoke Therapeutics (CIK: 0001623526) have changed. This matters to investors because insider activity, especially buying or selling, can provide clues about management's confidence in the company's future prospects.

Why It Matters

Insider filings like this can signal changes in a key person's stake, which investors often watch for insights into the company's health and future outlook.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change in beneficial ownership, and does not inherently carry significant risk without transaction details.

Analyst Insight

An investor should note this filing and then look for the actual transaction details within the full Form 4 document to understand if Allan Jonathan bought or sold shares, and in what quantity, to gauge potential insider sentiment.

Key Players & Entities

• Allan Jonathan (person) — Reporting Person
• Stoke Therapeutics, Inc. (company) — Issuer
• 0001966716 (person) — CIK for Allan Jonathan
• 0001623526 (company) — CIK for Stoke Therapeutics, Inc.

FAQ

Key Financial Figures

• $33.33 — ple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The rep
• $34.28 — ctions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting per
• $34.34 — ple transactions at prices ranging from $34.34 to $35.12 per share, inclusive. /s/ Jo
• $35.12 — ctions at prices ranging from $34.34 to $35.12 per share, inclusive. /s/ Jonathan All

Filing Documents

• form4-03242026_080316.html (4)
• form4-03242026_080316.xml (4) — 6KB
• 0001966716-26-000008.txt ( ) — 7KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Allan Jonathan (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE (Street) BEDFORD MASSACHUSETTS 01730 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [ STOK ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) GENERAL COUNSEL & CORP SEC 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/20/2026 S (1) 8,692 D $ 33.6354 (2) 20,144 D Common Stock 03/20/2026 S (1) 601 D $ 34.4079 (3) 19,543 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive. /s/ Jonathan Allan 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR